摘要
目的:基于生物信息学分析以及qPCR技术探究RSRC1在非小细胞肺癌(Non-small cell lung cancer, NSCLC)中的表达和临床价值。方法:结合癌症基因组图谱等多种数据库分析RSRC1在肿瘤中的表达与NSCLC病人的预后、病理学特征以及肿瘤免疫之间的关系并对RSRC1及其相关基因进行富集分析。通过qPCR技术验证RSRC1在NSCLC细胞株中的表达。结果:RSRC1在NSCLC以及其主要亚型中均表达升高。RSRC1的表达水平在NSCLC中与患者的预后、临床病理特征、免疫细胞以及免疫微环境均密切相关。RSRC1在NSCLC中可能参与细胞周期、DNA复制等生物学过程。RSRC1在NSCLC细胞株中mRNA表达升高。结论:RSRC1是NSCLC中一种重要的生物标志物,有成为NSCLC治疗靶点的潜力。
Objective: Exploring the expression and clinical value of RSRC1 in NSCLC based on bioinformatics analysis and qPCR technology. Methods: Analyzing the relationship between the expression of RSRC1 in tumors and the prognosis, pathological characteristics, and tumor immunity of NSCLC patients by combining multiple databases such as the Cancer Genome Atlas (TCGA), and performing enrichment analysis on RSRC1 and its related genes, verifying the expression of RSRC1 in NSCLC cell lines through qPCR technology. Results: RSRC1 is upregulated in NSCLC and its major subtypes. The expression level of RSRC1 is closely related to the prognosis, clinical pathological indicators, immune cells, and immune microenvironment of NSCLC patients. RSRC1 may be involved in biological processes such as cell cycle and DNA replication in NSCLC. RSRC1 mRNA expression is elevated in NSCLC cell lines. Conclusion: RSRC1 is an important biomarker of NSCLC and has potential as a therapeutic target for NSCLC.
出处
《临床医学进展》
2024年第7期102-111,共10页
Advances in Clinical Medicine